Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Completed 4

Sponsor Class

OTHER 6INDUSTRY 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Classical hematology 2Tumor-Agnostic 1

Conditions

Neoplasms 2Non-hematological Malignancies 1Anemia, Iron-Deficiency 1Anemia 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × iron isomaltoside 1000 × Clear all
NCT04318405 2023-07-19

Real-CHOICE

Pierre Fabre Pharma AG

Completed
327 enrolled
Classical hematology

Anemia, Iron-Deficiency

NCT01145638 2015-12-03

A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Pharmacosmos A/S

Phase 3 Completed
350 enrolled 9 charts
Tumor-Agnostic

Neoplasms

NCT01213979 2013-06-27

PK-CIA-04

Pharmacosmos A/S

Phase 1 Completed
16 enrolled

Non-hematological Malignancies

NCT01280240 2013-06-04

PK-CIA-06

Pharmacosmos A/S

Phase 1 Completed
11 enrolled
Classical hematology

Anemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡